Chandigarh [India], April 26 (ANI): The city-based Post- Graduate Institute of Medical Education and Research (PGIMER) on Sunday said that it has assessed the safety of mycobacterial w (Mw), an immunomodulator for leprosy, in four hospitalised patients of COVID-19, and has found no short-term adverse effect."In the pre-study phase, we have assessed the safety of Mw in four hospitalised patients of COVID-19 and have found no short-term adverse effect. The impact of Mw use on long term safety and efficacy will only be known after the conclusion of this CSIR-supported clinical trial, which will be initiated soon at all three centres," said the PGIMER in a statement.PGIMER-Chandigarh, AIIMS-Delhi, and AIIMS-Bhopal will study the use of Mw -- heat-killed mycobacterium indicus pranii -- as an adjunct to the treatment of critically ill COVID-19 patients.Mycobacterium w originally developed as an immunomodulator for leprosy acts through the toll-like receptor pathway and enhances host-T cell responses."In a recently concluded multi-centre trial, we found that Mw reduces mortality in ICU patients with severe sepsis. Mw can potentially decrease the cytokine storm seen in patients with COVID-19, and may thus be of potential benefit in managing these patients and decreasing mortality," the statement read.India has so far reported 26,496 COVID-19 patients and 824 deaths caused by the deadly virus across the country. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)